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Summary Sleep disorder specialists manage 90% of patients suffering from obstructive sleep
apnoea, which affects 10% of the general population. From another perspective, cardiovascular
disease specialists are particularly challenged by sleep apnoea, since it affects a large propor-
tion of their patients and its complications are largely cardiovascular. At least 50% of patients
with chronic heart failure (HF) suffer from sleep apnoea, predominantly central and/or Cheyne-
Stokes respiration as opposed to obstructive sleep apnoea. While its effect on survival remains
uncertain, sleep apnoea promotes the progression of chronic HF and is a predictor of poor prog-
nosis. After screening by cardiologists, patients presenting with chronic HF and sleep apnoea
should be referred to a sleep disorder specialist for diagnostic conﬁrmation and treatment.
In Part I of this review, we describe the diagnostic steps recommended when sleep apnoea is
suspected in patients with chronic HF. We also review the deﬁnitions of abnormal sleep-related
respiratory events and the prevalence, pathophysiology and haemodynamic consequences of
sleep apnoea in this patient population.
© 2009 Elsevier Masson SAS. All rights reserved.
Abbreviations: AHI, Apnoea-hypopnoea index; CO2, Carbon dioxide; CompSAS, Complex sleep apnoea syndrome; CSA, Central sleep
apnoea; CSR, Cheyne-Stokes respiration; HF, Heart failure; LV, Left ventricular; OSA, Obstructive sleep apnoea; O2, Oxygen; ODI, Oxygen
desaturation index.
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MOTS CLÉS
Apnée du sommeil ;
Insufﬁsance
cardiaque
à la recherche de l’AS chez les insufﬁsants cardiaques. Également, nous rappelons les déﬁnitions
des différents évènements respiratoires anormaux pendant le sommeil, ainsi que la prévalence,
la physiopathologie et les conséquences hémodynamiques de l’AS dans l’insufﬁsance cardiaque.
© 2009 Elsevier Masson SAS. Tous droits réservés.
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leep disorder specialists manage 90% of patients suffering
rom obstructive sleep apnoea (OSA), which affects 10% of
he general population [1]. At least 50% of patients suffer-
ng from chronic heart failure (HF) also suffer from sleep
pnoea. Studies in these patients suggest a predominance
f central sleep apnoea and/or Cheyne-Stokes respiration
CSA/CSR) versus OSA [2—14]. CSA/CSR promotes the pro-
ression of chronic HF and is independently associated with
decreased survival rate [5,7,8,15—17]. OSA may also be
n independent predictor of increased mortality in patients
ith chronic HF [18,19]. Whether sleep apnoea is a marker
f severe chronic HF or is directly responsible for abbreviat-
ng life is unclear [5,7,13,20,21]. These observations have
parked an interest in sleep apnoea among patients suf-
ering from chronic HF, a notorious public health burden
ssociated with a high mortality, making the management
f sleep apnoea in patients with chronic HF a medicosocial
riority. In Part I of this review, we describe the diagnos-
ic steps recommended when sleep apnoea is suspected in
atients with chronic HF. We also review the deﬁnitions of
bnormal sleep-related respiratory events and the preva-
ence, pathophysiology and haemodynamic consequences of
leep apnoea in this patient population.
iagnosis of sleep apnoea
history of daytime sleepiness suggests a common form of
SA associated with marked sleep fragmentation, which may
e screened using the Epworth sleepiness scale score or the
erlin questionnaire. In patients presenting with chronic HF,
his screening method reliably identiﬁes OSA in the major-
ty of individuals [18] but not CSA/CSR. Furthermore, the
istory and physical examination of patients suffering from
hronic HF is less likely to suggest the presence of sleep
pnoea, since their rate of obesity is lower than among
atients presenting with the common form of OSA [2,4,11]
nd because patients with CSA/CSR are notably less likely
o complain from daytime sleepiness [2]. In patients with
d
n
t
c
ihronic HF, an arterial carbon dioxide (CO2) concentration
ess than 35mmHg, during the daytime or at night, may be a
ign of CSA/CSR, although it is not consistently present [22].
n these patients, a home nocturnal pulse ﬁnger oxymetry
onitor might be a more reliable ﬁrst diagnostic step than
questionnaire or blood gases to conﬁrm the presence of
uspected sleep apnoea [23]. These monitors can be com-
ined with airﬂow signals recorded from a nasal cannula.
he programming of these instruments, their placement on
he patient and the interpretation of the recordings are sim-
le and expeditious and can be implemented by physicians
ho are not sleep disorder specialists. The recordings can be
cored using the automated analysis protocol of the device
oftware. The oxygen (O2) desaturation index (ODI) is the
ean hourly number of less than or equal to 3% or 4% dips in
2 lasting greater than or equal to 10 s, occurring immedi-
tely after the baseline arterial O2 saturation signal. An ODI
reater than or equal to 12 indicates a high probability of
leep apnoea (Fig. 1). The sensitivity of ODI in the detection
f sleep apnoea in patients with chronic HF is 100%, although
ts accuracy in the distinction between OSA and CSA/CSR is
ess than 20% [23]. Given:
the paucity of sleep apnoea-related symptoms and the
high prevalence of sleep apnoea among patients with
chronic HF;
the high morbidity and mortality associated with sleep
apnoea in that population;
the availability of simple and expeditious nocturnal
oxymetry monitoring, their systematic screening seems
appropriate, despite the high number of candidates that
this represents.
The next diagnostic step requires the expertise of a
leep disorder specialist, who performs and interprets
he polysomnographic or nocturnal ventilation polygraphic
ecordings, to conﬁrm the diagnosis of sleep apnoea andP. Bordier
Résumé Les somnologues prennent en charge 90% de patients atteints d’apnée du sommeil
(AS) de nature obstructive, problème touchant 10 % de la population générale. Les spécialistes
des maladies cardiovasculaires sont aussi particulièrement concernés par cette affection car sa
prévalence est élevée chez leurs patients et les principales complications de l’AS sont d’ordre
cardiovasculaire. Plus de la moitié des insufﬁsants cardiaques chroniques ont une AS, plus sou-
vent de type central, et/ou respiration de Cheyne-Stokes, qu’obstructif. On considère que l’AS
favorise la progression de l’insufﬁsance cardiaque et sa présence chez un insufﬁsant cardiaque
est associée à une surmortalité mais sans que la responsabilité de l’AS ne soit établie. Après un
dépistage d’AS positif réalisé par le cardiologue chez un insufﬁsant cardiaque, le patient doit
être conﬁé à un somnologue aﬁn de conﬁrmer le diagnostic et discuter la prise en charge. Dans
la partie I de cette revue, nous décrivons les étapes diagnostiques pouvant être proposées quantetermine its type and severity. While polygraphy does
ot include neurophysiological sleep variables, unlike elec-
roencephalography or electromyography, it allows the
onﬁrmation of sleep apnoea. A polygraphic recording can
nclude measurements of:
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Figure 1. Detection of sleep apnoea by nocturnal pulse ﬁnger oxymetry. Top tracing: recording of normal nocturnal oxymetry. The
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Cother tracings are recordings from three different patients, with au
desaturation index (number of dips in O2 per hour of nocturnal reco
min is displayed on the horizontal axis.
• continuous airﬂow by a nasal cannula pressure transducer;
• nasal and oral airﬂow via a thermistor;
• rib cage and abdominal motion for breathing efforts,
using respiratory inductive plethysmograph or piezoelec-
tric sensor belts;
• arterial O2 saturation and heart rate by pulse ﬁnger
oximetry;
• synchronized, single- or multichannel electrocardio-
grams.
Deﬁnitions
‘‘Apnoea’’ is the complete cessation of oronasal airﬂow last-
ing for more than or equal to 10 s (Fig. 2) [24]. Among several
deﬁnitions, ‘‘hypopnoea’’ is a greater than or equal to 30%
decrease in the amplitude of inspiratory oronasal airﬂow
below the surrounding baseline, lasting for more than or
equal to 10 s, and accompanied by a greater than or equal
I
i
t
atically calculated ODI≥ 12, consistent with sleep apnoea. ODI: O2
); SpO2: arterial O2 saturation, on the vertical axis. Time in h and
o 3 or 4% decrease in O2 saturation from a previous stable
aseline (Fig. 3). A greater than or equal to 90% decrease in
he amplitude of oronasal airﬂow is scored as an apnoea. The
atterns of apnoea and hypopnoea are obstructive, central
r mixed.
bstructive respiratory events
n obstructive respiratory event is caused by obstruction of
he inspiratory airﬂow through the upper airways, associated
ith ongoing respiratory efforts and out-of-phase motion of
he rib cage and abdomen (Figs. 2 and 3).
entral respiratory eventsmpairment of the central respiratory drive during sleep
s the cause of central respiratory events. The respira-
ory efforts and the thoracic and abdominal movements
re absent during central apnoea (Fig. 4) and are weak-
654 P. Bordier
Figure 2. Obstructive apnoea documented by nocturnal ventilation polygraphy. The recordings shows typical repetitive apnoeic events,
each associated with profound dips in blood O2 saturation and autonomic nervous system instability characterized by marked bradycardia
caused by vagal stimulation during apnoea, followed by tachycardia due to sympathetic surge at the end of each apnoeic episode. See text
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ned and associated with in-phase motion of the rib
age and abdomen during central hypopnoea (Fig. 5).
racings of ‘‘Cheyne-Stokes respiration’’ are shown in
igs. 5 and 6, with, respectively, hypopnoea and apnoea
ccurring between two cycles of hyperventilation. These
bnormal respiratory events are characterized by repetitive
pisodes of apnoea or hypopnoea lasting for more than or
qual to 10 s, alternating with greater than or equal to three
ycles of crescendo-decrescendo airﬂow during the hyperp-
oeic phase, at a rate of greater than or equal to 10 episodes
er hour. This periodic breathing is typically observed in
atients suffering from chronic HF or after major strokes.
ixed respiratory events
mixed respiratory event is typically an apnoea, charac-
erized by a central, followed by obstructive, pattern of
horacic and abdominal movements, while the airﬂow wave-
orm remains ﬂat (Fig. 7). It can also be a central apnoea,
uring which the absence of breathing effort progresses into
n-phase thoracoabdominal movements of growing ampli-
ude, while the airﬂow waveform remains ﬂat.
s
a
m
w
rObstructive, central and mixed respiratory events may
e present on the same overnight recording [3,24]. Sleep
pnoea is ‘‘central’’ when greater than or equal to 50%
f the abnormal respiratory events are of central origin
2,4,20,24], and ‘‘obstructive’’ when greater than or equal
o 50% of the events are obstructive or mixed. The diagnosis
f sleep apnoea is based on the value of the apnoea-
ypopnoea index (AHI), calculated by dividing all episodes of
pnoea and hypopnoea by the number of hours of sleep dur-
ng polysomnography, or by the duration of recording during
olygraphy. Sleep apnoea is absent when AHI is less than 5,
ild between 5 and 15, moderate between 15 and 30 and
evere when AHI is greater than or equal to 30 [5,8,24].
n AHI greater than or equal to 30 has been associated
ith an increased mortality in patients with OSA [18,19,25],
nd in patients with CSA/CSR and chronic HF [5,7,16]. In
hat latter population, an up to 36% prevalence of severe
leep apnoea has been reported [5,8]. In a same patient
nd under similar conditions of recording, the measure-
ents of AHI remain stable. In 19 patients with chronic HF
ho underwent four consecutive nocturnal recordings, AHI
anged from 32.1± 14 to 34.2± 14 [26]. In another group of
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•Figure 3. Obstructive hypopnoea documented by nocturnal vent
autonomic nervous system instability associated with the dips in O
cardiac pacing. See text for more detailed explanations.
50 patients suffering from chronic HF, the mean variability
of AHI between two consecutive nocturnal recordings was
1.4± 5.0 [27].
An AHI greater than or equal to 15 is generally considered
an indication for treatment of sleep apnoea [2,8,20,21].
Treatment is considered effective when:
• AHI has decreased by greater than or equal to 50%;
• is lowered to less than or equal to 10 or greater than or
equal to 15;
• or both [21].
In studies on sleep apnoea, responders versus non-
responders to treatments have been deﬁned on the basis
of statistically signiﬁcant changes in AHI from baseline, or
on the basis of a decrease in the severity of sleep apnoea
graded according to the AHI value.
Patients with OSA may develop manifestations of CSA dur-
ing titration of nasal continuous positive airway pressure
[28]. The mechanisms behind this phenomenon, known as
complex sleep apnoea syndrome (CompSAS), remain unclear.
It is observed in 10% of patients suffering from sleep-
disordered breathing and is sometimes associated with CSR.
CompSAS is observed predominantly in patients without
chronic HF. However, patients who suffer from chronic HF
often present with a mixed central and obstructive form of
sleep apnoea and with both apnoea and hypopnoea. There-
fore, the term ‘‘complex’’ should be reserved for a clearly
deﬁned underlying pathological substrate. From a thera-
peutic standpoint, the management of ‘‘complex’’ formsn polygraphy. In this example, the variations in heart rate due to
uration during each hypopnoeic event are masked by permanent
f sleep apnoea in patients with chronic HF is particularly
hallenging.
revalence of sleep apnoea in heart
ailure
n studies of patients with chronic HF and sleep apnoea, the
eﬁnition of chronic HF has been based on a depressed left
entricular (LV) ejection fraction, measured by echocardio-
raphy or radionuclide angiography, varying between less
han or equal to 55% and less than or equal to 35%. Some
tudies have included episodes of cardiac decompensation,
r a stable, high New York Heart Association functional class,
r both. The variable prevalence of sleep apnoea among
tudies is, therefore, explained by:
the variable severity of chronic HF among enrolment cri-
teria;
the variable methods of patients enrolment, based on
the functional manifestations of sleep apnoea or on the
presence of chronic HF only;
on the variable scoring of the sleep recordings and the
use of an AHI greater than or equal to 5, versus greater
than or equal to 10 versus greater than or equal to 15 to
diagnose sleep apnoea. Table 1 shows the prevalence of
OSA and CSA/CSR in patients with a LV ejection fraction
less than or equal to 35% and a greater than or equal to
10 or greater than or equal to 15 AHI diagnostic cut-off
656 P. Bordier
F olyg
a ea. S
P
f
T
o
u
d
a
n
b
i
C
o
C
t
O
c
c
t
i
S
e
i
o
c
b
i
p
o
e
O
a
t
r
T
r
f
r
t
m
v
c
cigure 4. Central apnoea documented by nocturnal ventilation p
re shown in this example, as often observed in central sleep apno
value. Others studies have conﬁrmed a high prevalence
of sleep apnoea among patients suffering from chronic
HF [5—7,14].
athophysiology of sleep apnoea in heart
ailure
he main part of the respiratory drive is located at the level
f the medulla oblongata. Among several ventilation reg-
latory factors, CO2 and O2 predominantly inﬂuence this
rive. The arterial partial pressure of CO2 is the baseline
nd, compared to the partial pressure for O2, the predomi-
ant respiratory stimulus. CO2 crosses freely the blood-brain
arrier and its concentration in the cerebrospinal ﬂuid
ncreases proportionally to that in the blood. In the blood,
O2 is predominantly buffered to HCO3− by the action
f carbonic anhydrase in erythrocytes (Haldane’s effect:
O2 + H2O HCO3- + H+). H+ ions produced by this reac-
ion are bound to the reduced haemoglobin generated by
2 released to the tissues, preventing blood acidosis. In
−ontrast, the capacity of CO2 buffering to HCO3 in the
erebrospinal ﬂuid is weak. Therefore, the CO2 concentra-
ion remains high, and albeit weak, the production of H+
ons cannot be buffered in the absence of haemoglobin.
ince pH=−log [H+] and since CO2 and H+ ions are consid-
a
•raphy. Moderate dips in O2 saturation and variations in heart rate
ee text for more detailed explanations.
red equivalent with respect to the acid-base balance, an
ncrease in the concentration of CO2 is an immediate cause
f cerebrospinal ﬂuid acidosis [29]. Medullary cells of the
entral chemoreceptors that are sensitive to CO2 and H+ (H+
eing most probably the main drive) respond to the decrease
n cerebrospinal ﬂuid pH by triggering an increase in res-
iratory muscles activity. Conversely, hypocapnic alkalosis
f the cerebrospinal ﬂuid causes hypoventilation. Periph-
ral chemoreceptors sensitive to the partial pressures of
2 and H+ are located in glomus cells of the aortic arch
nd in the carotid body, with afferent neural pathways to
he medulla via, respectively, the vagus and the glossopha-
yngeal nerves [30]. Hypoxaemia causes hyperventilation.
he phrenic nerve is one of the main drivers of the respi-
atory muscles. However, vagal and sympathetic efferents
rom the brainstem are also involved prominently in inspi-
atory and expiratory efforts as well as in the activity of
he pharyngeal muscles and are under the inﬂuence of the
edullary response to the partial pressure of O2 and to the
enous, more than arterial, PCO2 concentration [31]. Any
hange in the medullary or arterial H+ ion concentration
auses a rapid ventilatory and slower renal compensatory
daptation.
Among CSA are distinguished:
hypercapnic syndromes with hypoventilation, such as
congenital central hypoventilation syndrome, respiratory
depressant effects of opioid-based medication, obesity
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Figure 5. Central hypopnoea documented by nocturnal ventilation polygraphy. This recording shows weak respiratory efforts accompanied
by an in-phase (as opposed to out-of-phase in obstructive events) decrease in rib cage and abdominal motion, proportional to the decrease
in airﬂow amplitude. The electrocardiogram shows a ﬁxed heart rate due to permanent pacing. Instead of apnoeic events, the tracings show
typical Cheyne-Stokes periodicity. See text for more detailed explanations.Figure 6. Cheyne-Stokes respiration documented by nocturnal ven
ing/decreasing motion of the thorax and abdomen and a proportional
shows a ﬁxed heart rate due to permanent pacing. See text for more detilation polygraphy. The recording shows an in-phase increas-
increase/decrease in airﬂow amplitude. The electrocardiogram
tailed explanations.
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xed heart rate, due to permanent cardiac pacing. See text for mo
hypoventilation syndrome and various neuromuscular dis-
orders;
normo- or hypocapnic syndromes with hyperventilation,
such as in CSA/CSR and idiopathic CSA [32]. CSA/CSR in
chronic HF appears closely related to the degree of car-
diac dysfunction, which destabilizes the respiratory drive.Several putative mechanisms of CSA/CSR have been
roposed as upstream and downstream myocardial conse-
uences of chronic HF. Downstream disorders commonly
bserved during advanced chronic HF include:
•
Table 1 Prevalence of obstructive and central sleep apnoea
equal to 35%, according to a ≥ 10 or ≥ 15 apnoea-hypopnoea in
Reference Number of patients Mean left ven
ejection frac
Gabor et al. [9] 28 20
Ferrier et al. [10] 53 34
Sin et al. [4] 450 27
Schulz et al. [12] 203 28
Javaheri et al. [2] 81 25
Oldenburg et al. [11] 700 28
Vazir et al. [13] 55 31
Sin et al. [4] 450 27
Lanfranchi et al. [8] 47 27
Tkacova et al. [3] 36 25
a Values are % of patients.phy. This example shows marked variations in O2 saturation with a
tailed explanations.
hyperventilation in the supine position and during sleep
[33,34], which promotes hypocapnia;
a prolonged circulation time [15], which corresponds to
the time elapsed between the end of an apnoeic event
and the nadir of the associated dip in O2, and which is
considered a surrogate measurement of the cardiac out-
put; prolongation of this time results in deeper hypoxia
and, subsequently, compensatory hyperventilation and
hypocapnia;
hypocapnia, the main cause of central apnoea, occurring
predominantly at night, though sometimes also observed
during the day time [22,32].
in patients with left ventricular ejection fraction less or
dex (AHI) cut-off value.
tricular
tion (%)
AHIa Sleep apnoeaa
≥ 10 ≥ 15 Obstructive Central
57 — 14 43
68 — 53 15
71 — 38 33
71 — 43 28
— 51 11 40
— 52 19 33
— 53 15 38
— 61 32 29
— 66 11 55
— 72 22 50
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Hypocapnia, via the central chemoreceptors, causes a
decrease in ventilatory amplitude and rate and, below
a threshold CO2 concentration, may cause apnoea [35].
In patients with chronic HF, compared to normal indi-
viduals, this apnoeic threshold seems lower during sleep
than during waking hours. The slowing or cessation of
ventilation causes a rise in CO2 and ventilation resumes
when the CO2 concentration has returned above the
apnoeic threshold. This cyclic phenomenon, or periodic
breathing, repeats itself in a sequence of crescendo
hyperventilation—decrescendo hypoventilation—respiratory
pause. The key role of hypocapnia is highlighted by the elim-
ination of CSA/CSR when patients suffering from chronic
HF and hypocapnia during daytime are treated with sup-
plemental inhaled CO2 during sleep [36]. The high nocturnal
pulmonary capillary wedge pressure present in the supine
position is one of the upstream complications of advanced
chronic HF [34,37]. It increases the pulmonary interstitial
pressure that stimulates the alveolar stretch receptors, from
which the signals are transmitted to the medulla via the glos-
sopharyngeal and vagus nerves. The medullary response via
vagal and sympathetic efferents slows the respiratory mus-
cles activity, decreases the tidal volume and ventilation rate
and promotes the development of central apnoea [38,39]. In
combination with pulmonary congestion, which inhibits the
respiratory reﬂex, acute hypoxia may prolong the duration
of apnoea.
In patients with chronic HF, obstructive respiratory
events may be due to OSA present before the development
of chronic HF, in which case the events are associated with
typical local ﬂaccidity and collapsibility of the pharyngeal
soft tissues. Alternatively, the obstructive events are caused
by chronic HF and are due to abnormal central respiratory
drive and central respiratory events. Normally, the respira-
tory drive sends simultaneous signals to the motor neurons
of the upper airway musculature leading to stiffening and
duct patency and to the diaphragm via the phrenic nerves,
triggering an inspiratory effort [40] and activating both mus-
cle territories synchronously. During central apnoea, the
absence of central respiratory drive decreases the tone of
the pharyngeal muscles, because of a decrease in the affer-
ent, phasic neural drive to these muscles. A cyclic decrease
in the activity of the diaphragms and pharyngeal muscles
has been observed in CSA/CSR and OSA [41,42]. The conse-
quences of a weak or immobile diaphragm are:
• a weak or absent intrathoracic depression;
• a weak or absent depression-obstruction at the pharyn-
geal level, resulting in a pattern of central respiratory
event.
If the diaphragm is only moderately weak, the intratho-
racic depression may be sufﬁcient to cause obstruction
of the upper airways, resulting in an obstructive pattern
induced by chronic HF. Another putative explanation is
the development of heart failure-induced tissue conges-
tion, obstructing the upper airways. In healthy subjects,
an oedematous overload of the upper body by antishock
trousers may contribute to OSA by narrowing the lumen
of the upper airways [43]. In patients with chronic HF,
OSA has been observed to precede CSA/CSR during the
ﬁrst part of nocturnal recordings. This has been attributed
to the haemodynamic deterioration caused by nocturnal
f
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SA, interfering in turn with the respiratory drive and pro-
oting the development of CSA/CSR. Mixed apnoea may
e the product of these intricate central and obstructive
echanisms that are activated in patients suffering from
hronic HF. Following the absence of airﬂow and thoracic
nd abdominal movements, breathing efforts resume with
ut-of-phase motion of the rib cage and abdomen, con-
istent with a state of upper airway obstruction. This is
robably due to the gradual return of respiratory muscle
ctivity and stiffening of the pharyngeal muscles, however
nsufﬁcient, to keep the upper airways properly open. If, at
hat moment, the upper airways remain unobstructed, the
reathing efforts resume with an in-phase motion of thorax
nd abdomen, appearing as momentary central hypopnoea
etween the apnoeic phase and the return of normal breath-
ng activity or hyperventilation.
aemodynamic consequences of sleep
pnoea
bstructive apnoea
bstruction to the upper inspiratory airﬂow generates
marked, negative intrathoracic pressure, as high as
50 cmH2O, compared to −10 cmH2O during normal inspi-
ation. This causes increases in the pressure differential
nside the LV, the LV diastolic pressure and, ultimately, the
V ﬁlling pressure [44,45]. In addition, the rises in hyper-
apnia and hypoxia that occur during apnoea trigger bursts
f central sympathetic nervous activity at the end of the
pnoeic phases, causing arousals that contribute to ending
he apnoea and explaining the sleep fragmentation. These
ursts may have peripheral manifestations, such as sinus
achycardia, blood pressure surges and increase in LV after-
oad [46,47]. Left atrial volume and LV systolic performance
ere both decreased in normal individuals, by reproducing
he marked negative intrathoracic pressure present during
bstructive respiratory events [48]. The apnoea-related neg-
tive intrathoracic pressure increases the venous return,
harply increasing the right ventricular and LV preloads [45].
he higher venous return also acutely distends the right ven-
ricle, causing paradoxical interventricular septal motion
hich accentuates the abnormal LV ﬁlling. Therefore, the
ffects of obstructive apnoea on the left and right heart cav-
ties may decrease the LV stroke volume. In a background of
hronic HF and elevated baseline LV diastolic pressure [49],
repetition of these obstructive apnoeic events is likely to
ecrease the cardiac output.
bstructive and central apnoea
pnoea-related dips in O2 deprive the myocardium from its
2 supply and may exacerbate LV failure [50], particularly
ince myocardial O2 demand increases simultaneously, and
ecause of the sympathetic surge that occurs at the end of
pnoea [15,33]. The increase in sympathetic activity causes
urther peripheral vasoconstriction, and increases the blood
ressure, heart rate [44] and LV afterload [46,47,51],
ecreasing the stroke volume. In addition, as observed in
ascular endothelium, one might hypothesize that the rep-
tition of hypoxic alternating with normoxic periods causes
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yocardial reperfusion injury from oxidative stress, with
ncreased production of free radicals and lipid peroxidation
52]. Finally, the repetitive nocturnal deprivation of myocar-
ial O2 is likely to promote the progression of chronic HF
15,33,53].
onclusions
he prevalence of sleep apnoea in patients with chronic HF
s high. Sleep apnoea promotes the progression of chronic HF
nd is a predictor of poor prognosis in patients with chronic
F. Its effect on survival, however, remains uncertain. The
anagement of sleep apnoea in patients with chronic HF is
n important endeavour. Cardiologists should participate in
he detection of sleep apnoea before referring their patients
or management by sleep disorder specialists.
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